Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01372475 · ClinicalTrials.gov registry record · Phase 3

Hymovis™ Versus Placebo in Knee Osteoarthritis

A Phase 3 study, sponsored by Fidia Farmaceutici s.p.a..

Completed
Registry status
Phase 3
Development phase
800
Enrollment target

NCT01372475 is a Phase 3 study that has completed, run by Fidia Farmaceutici s.p.a.. The registered enrollment target is 800 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01372475, a Phase 3 study, has completed, sponsored by Fidia Farmaceutici s.p.a..

COMPLETED
Registry status
Phase 3
Development phase
800 participants
Enrollment target

Study Summary

Purpose: The purpose of this study is to demonstrate if the intra-articular injection of a new viscoelastic Hydrogel (Hymovis) is superior to Placebo (phosphate buffered saline \[PBS\] in subjects with symptomatic osteoarthritis of the knee.

Interventions

  • DEVICE Hymovis Intra-articular Injection
  • PROCEDURE Phosphate Buffered Saline Injection

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2011-03
Est. Completion 2013-02
Phase Phase 3

Sponsor

Fidia Farmaceutici s.p.a.

2 total trials

What the Registry Record Tells You About NCT01372475

The ClinicalTrials.gov registry entry for NCT01372475 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fidia Farmaceutici s.p.a., which has 2 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Hymovis Intra-articular Injection is the first listed.

NCT01372475 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01372475 about?

NCT01372475 is a clinical study titled "Hymovis™ Versus Placebo in Knee Osteoarthritis". Purpose: The purpose of this study is to demonstrate if the intra-articular injection of a new viscoelastic Hydrogel (Hymovis) is superior to Placebo (phosphate buffered saline \[PBS\] in subjects with symptomatic osteoarthritis of the knee.

What is the current status of trial NCT01372475?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2011-03. Estimated completion is 2013-02.

What interventions are being tested in trial NCT01372475?

The interventions under investigation include: Hymovis Intra-articular Injection (DEVICE), Phosphate Buffered Saline Injection (PROCEDURE).

Who is sponsoring clinical trial NCT01372475?

This trial is sponsored by Fidia Farmaceutici s.p.a., which has 2 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.